EA201792329A1 - Способ мономеризации рекомбинантных молекул антител - Google Patents
Способ мономеризации рекомбинантных молекул антителInfo
- Publication number
- EA201792329A1 EA201792329A1 EA201792329A EA201792329A EA201792329A1 EA 201792329 A1 EA201792329 A1 EA 201792329A1 EA 201792329 A EA201792329 A EA 201792329A EA 201792329 A EA201792329 A EA 201792329A EA 201792329 A1 EA201792329 A1 EA 201792329A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibody molecules
- monomerization
- recombinant antibody
- composition
- reducing agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
- C07K5/123—Tripeptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1506870.3A GB201506870D0 (en) | 2015-04-22 | 2015-04-22 | Method |
| PCT/EP2016/059051 WO2016170138A1 (en) | 2015-04-22 | 2016-04-22 | Method of monomerisation of recombinant antibody molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201792329A1 true EA201792329A1 (ru) | 2018-02-28 |
Family
ID=53299019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201792329A EA201792329A1 (ru) | 2015-04-22 | 2016-04-22 | Способ мономеризации рекомбинантных молекул антител |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10828366B2 (https=) |
| EP (1) | EP3286204B1 (https=) |
| JP (1) | JP6898251B2 (https=) |
| KR (1) | KR20170138552A (https=) |
| CN (1) | CN108064230B (https=) |
| AU (1) | AU2016251620A1 (https=) |
| BR (1) | BR112017021812A2 (https=) |
| CA (1) | CA2981644C (https=) |
| CL (1) | CL2017002676A1 (https=) |
| CO (1) | CO2017010385A2 (https=) |
| EA (1) | EA201792329A1 (https=) |
| ES (1) | ES2846732T3 (https=) |
| GB (1) | GB201506870D0 (https=) |
| IL (1) | IL254765A0 (https=) |
| MX (1) | MX2017013376A (https=) |
| SG (1) | SG11201708151TA (https=) |
| WO (1) | WO2016170138A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201223276D0 (en) * | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| KR102537099B1 (ko) | 2014-12-22 | 2023-05-25 | 유씨비 바이오파마 에스알엘 | 단백질 제조 방법 |
| GB201506868D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
| GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| AU2019356564A1 (en) * | 2018-10-11 | 2021-04-29 | Amgen Inc. | Downstream processing of bispecific antibody constructs |
| JP7607564B2 (ja) * | 2018-12-21 | 2024-12-27 | ノバルティス アーゲー | Ｐｍｅｌ１７に対する抗体及びその結合体 |
| WO2022122654A1 (en) * | 2020-12-07 | 2022-06-16 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| US5453363A (en) | 1985-10-23 | 1995-09-26 | Boehringer Mannheim Gmbh | Process for the activation of t-PA or Ing after genetic expression in prokaryotes |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| DK0580737T3 (da) | 1991-04-10 | 2004-11-01 | Scripps Research Inst | Heterodimere receptorbiblioteker ved anvendelse af phagemider |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| AU675929B2 (en) * | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
| PT1231268E (pt) | 1994-01-31 | 2005-11-30 | Univ Boston | Bancos de anticorpos policlonais |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| ATE511543T1 (de) * | 1999-02-22 | 2011-06-15 | Univ Georgetown | Immunoliposome mit einem targeting- antikörperfragment zur systemischen genverabreichung |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| SI2371392T1 (sl) | 2002-05-02 | 2015-10-30 | Wyeth Holdings Llc | Konjugati derivat-nosilec kaliheamicina |
| AU2003223936A1 (en) * | 2002-05-17 | 2003-12-02 | Kobenhavns Universitet | Method for purifying denatured proteins having a desired disulfide bond configuration |
| US7993864B2 (en) | 2002-12-03 | 2011-08-09 | Ucb Pharma S.A. | Assay for identifying antibody producing cells |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| ES2551439T5 (es) | 2003-07-01 | 2018-11-08 | Ucb Biopharma Sprl | Fragmentos Fab de anticuerpos modificados |
| GB0315450D0 (en) * | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| KR20120064120A (ko) | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
| US20060051347A1 (en) | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
| JP5553963B2 (ja) * | 2004-10-22 | 2014-07-23 | アムジエン・インコーポレーテツド | 組換え抗体をリフォールディングする方法 |
| JP2009504571A (ja) | 2005-07-25 | 2009-02-05 | トルービオン ファーマスーティカルズ インコーポレイテッド | タンパク質解離のための組成物および方法 |
| EP1929073A4 (en) | 2005-09-27 | 2010-03-10 | Amunix Inc | PROTEIN MEDICAMENT AND ITS USE |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| WO2009040562A1 (en) | 2007-09-26 | 2009-04-02 | Ucb Pharma S.A. | Dual specificity antibody fusions |
| EP2321338A1 (en) | 2008-08-14 | 2011-05-18 | Merck Sharp & Dohme Corp. | Methods for purifying antibodies using protein a affinity chromatography |
| HRP20170374T1 (hr) | 2008-09-26 | 2017-05-05 | Ucb Biopharma Sprl | Biološki proizvodi |
| BRPI0919034A8 (pt) * | 2008-09-26 | 2016-02-10 | Schering Corp | Métodos para produzir uma proteína e um anticorpo, meio líquido aquoso para cultura, e, vaso |
| LT3660032T (lt) | 2009-06-25 | 2026-02-25 | Amgen Inc. | Ne žinduolių sistemoje ekspresuotų baltymų surišamojo gryninimo būdai |
| US20120283415A1 (en) | 2009-09-10 | 2012-11-08 | Ucb Pharma S.A. | Multivalent Antibodies |
| GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| MX2012010661A (es) * | 2010-03-17 | 2013-03-25 | Biogenerix Gmbh | Metodo para obtener factor estimulante de colonias de granulocitos (g-csf) humano recombinante biologicamente activo. |
| WO2011117653A1 (en) | 2010-03-25 | 2011-09-29 | Ucb Pharma S.A. | Disulfide stabilized dvd-lg molecules |
| GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| JP5903101B2 (ja) * | 2010-09-20 | 2016-04-13 | バイオ−ラッド ラボラトリーズ インコーポレーティッド | クロマトグラフィーにおける生成物と複合体形成した夾雑物の分離方法 |
| US8759617B2 (en) * | 2010-09-21 | 2014-06-24 | National Institute Of Agrobiological Sciences | Method for extraction and purification of recombinant proteins from transgenic plants |
| CA2847888A1 (en) * | 2011-09-09 | 2013-03-14 | Biomed Realty, L.P. | Methods and compositions for controlling assembly of viral proteins |
| AU2012335496B2 (en) * | 2011-11-11 | 2017-05-11 | Ucb Biopharma Sprl | Albumin binding antibodies and binding fragments thereof |
| UA112203C2 (uk) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
| US20160060291A1 (en) * | 2012-03-30 | 2016-03-03 | Biogenomics Limited | Process for renaturation of polypeptides |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| CN113201073A (zh) | 2012-11-21 | 2021-08-03 | 詹森生物科技公司 | 双特异性EGFR/c-Met抗体 |
| CN106133137A (zh) | 2014-03-07 | 2016-11-16 | 生物纳米基因公司 | 多核苷酸的处理 |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506868D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
| GB201506870D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| JP2019533135A (ja) | 2016-08-12 | 2019-11-14 | ロンザ リミテッドＬｏｎｚａ Ｌｉｍｉｔｅｄ | 宿主細胞タンパク質のプロテオーム解析 |
-
2015
- 2015-04-22 GB GBGB1506870.3A patent/GB201506870D0/en not_active Ceased
-
2016
- 2016-04-22 AU AU2016251620A patent/AU2016251620A1/en not_active Abandoned
- 2016-04-22 CA CA2981644A patent/CA2981644C/en active Active
- 2016-04-22 WO PCT/EP2016/059051 patent/WO2016170138A1/en not_active Ceased
- 2016-04-22 ES ES16719824T patent/ES2846732T3/es active Active
- 2016-04-22 EA EA201792329A patent/EA201792329A1/ru unknown
- 2016-04-22 US US15/566,307 patent/US10828366B2/en active Active
- 2016-04-22 EP EP16719824.1A patent/EP3286204B1/en active Active
- 2016-04-22 MX MX2017013376A patent/MX2017013376A/es unknown
- 2016-04-22 JP JP2017555223A patent/JP6898251B2/ja not_active Expired - Fee Related
- 2016-04-22 BR BR112017021812A patent/BR112017021812A2/pt not_active Application Discontinuation
- 2016-04-22 SG SG11201708151TA patent/SG11201708151TA/en unknown
- 2016-04-22 CN CN201680022972.8A patent/CN108064230B/zh not_active Expired - Fee Related
- 2016-04-22 KR KR1020177033853A patent/KR20170138552A/ko not_active Abandoned
-
2017
- 2017-09-28 IL IL254765A patent/IL254765A0/en unknown
- 2017-10-11 CO CONC2017/0010385A patent/CO2017010385A2/es unknown
- 2017-10-20 CL CL2017002676A patent/CL2017002676A1/es unknown
-
2020
- 2020-10-23 US US17/078,127 patent/US11786593B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| GB201506870D0 (en) | 2015-06-03 |
| IL254765A0 (en) | 2017-12-31 |
| JP6898251B2 (ja) | 2021-07-07 |
| AU2016251620A1 (en) | 2017-10-26 |
| US20210069328A1 (en) | 2021-03-11 |
| CN108064230B (zh) | 2021-04-06 |
| EP3286204A1 (en) | 2018-02-28 |
| SG11201708151TA (en) | 2017-11-29 |
| CN108064230A (zh) | 2018-05-22 |
| BR112017021812A2 (pt) | 2018-07-10 |
| CA2981644A1 (en) | 2016-10-27 |
| JP2018515449A (ja) | 2018-06-14 |
| EP3286204B1 (en) | 2020-11-18 |
| US11786593B2 (en) | 2023-10-17 |
| KR20170138552A (ko) | 2017-12-15 |
| WO2016170138A1 (en) | 2016-10-27 |
| CO2017010385A2 (es) | 2018-03-20 |
| CL2017002676A1 (es) | 2018-03-23 |
| MX2017013376A (es) | 2017-12-07 |
| ES2846732T3 (es) | 2021-07-29 |
| US20180117153A1 (en) | 2018-05-03 |
| CA2981644C (en) | 2023-07-04 |
| US10828366B2 (en) | 2020-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201792329A1 (ru) | Способ мономеризации рекомбинантных молекул антител | |
| JOP20200078A1 (ar) | أجسام مضادة خاصة بـ cd47 وpd-l1 | |
| EA201491571A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| PE20181805A1 (es) | Composiciones y anticuerpos anti-tim-3 | |
| EA201891983A1 (ru) | Комбинированная терапия антителами к cd73 | |
| PH12019502298A1 (en) | Monoclonal antibody to pd-l1 | |
| AR104280A1 (es) | Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos | |
| EA201591153A1 (ru) | Антитела, связывающиеся с tl1a, и их применение | |
| PE20201171A1 (es) | Anticuerpos de cadena pesada que se unen a cd22 | |
| CL2016001028A1 (es) | Anticuerpos de alta afinidad y de agregación estable basados en dominios variables de vl y derivados de vhh. | |
| EA201792325A1 (ru) | Способ увеличения процентного содержания мономерного антитела в fab-dsfv мультимерных частицах | |
| UA120047C2 (uk) | Антигензв'язуючий фрагмент антитіла, який специфічно зв'язується з рецептором інсуліноподібного фактора росту 1 (igf1r) | |
| EA201991464A1 (ru) | АНТИТЕЛО К α-СИНУКЛЕИНУ И ЕГО ПРИМЕНЕНИЕ | |
| EA202092420A1 (ru) | Антитело против pd-l1 и его применение | |
| EA202091747A1 (ru) | Составы антитела b7-h4 | |
| EA201790816A1 (ru) | Антитела, которые связываются с ccr6, и варианты применения указанных антител | |
| JOP20210286A1 (ar) | جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr | |
| CR20220660A (es) | Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2 | |
| EA202191666A1 (ru) | Антитела к il-27 и их применение | |
| MX2020009277A (es) | Anticuerpos anti-phf-tau y usos de estos. | |
| EA201891990A1 (ru) | Слитые белки на основе рекомбинантного фоллистатина и fc-фрагмента и их применение в лечении мышечной дистрофии дюшенна | |
| EA201990895A1 (ru) | Антитела к о1 и варианты их применения | |
| EA201891529A1 (ru) | Композиции и способы обнаружения и лечения рака яичников | |
| EA201691414A1 (ru) | Антитела к матриксной металлопротеиназе 9 и способы их применения |